GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) » Definitions » Interest Coverage

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Interest Coverage : 1.94 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Operating Income for the three months ended in Dec. 2023 was E£114 Mil. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Expense for the three months ended in Dec. 2023 was E£-59 Mil. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's interest coverage for the quarter that ended in Dec. 2023 was 1.94. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage or its related term are showing as below:

CAI:RMDA' s Interest Coverage Range Over the Past 10 Years
Min: 1.9   Med: 2.62   Max: 3.77
Current: 2.28


CAI:RMDA's Interest Coverage is ranked worse than
81.01% of 690 companies
in the Drug Manufacturers industry
Industry Median: 12.26 vs CAI:RMDA: 2.28

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Interest Coverage Historical Data

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Interest Coverage Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial 2.02 1.90 2.96 3.77 2.28

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 2.80 2.15 2.46 1.94

Competitive Comparison of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage falls into.



Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Expense was E£-191 Mil. Its Operating Income was E£436 Mil. And its Long-Term Debt & Capital Lease Obligation was E£12 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2023 )/Interest Expense (A: Dec. 2023 )
=-1*436.454/-191.199
=2.28

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Expense was E£-59 Mil. Its Operating Income was E£114 Mil. And its Long-Term Debt & Capital Lease Obligation was E£12 Mil.

Interest Coverage=-1* Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*113.96/-58.604
=1.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents  (CAI:RMDA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Interest Coverage Related Terms

Thank you for viewing the detailed overview of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. It is engaged in the manufacture and sale of branded generic pharmaceutical products nutraceuticals, cosmeceuticals, food supplements, medical devices, and veterinary products. The firm is engaged in therapeutic areas namely systemic anti-infectives, alimentary tract and metabolism, genitourinary system and sex hormones, cardiovascular system, nervous system, and blood and blood-forming organs.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Headlines

No Headlines